Skip to main content
. 2022 Jun 15;14:909222. doi: 10.3389/fnagi.2022.909222

FIGURE 8.

FIGURE 8

(A) The transfection efficiency of miR-26a-5p (miR-26a-5p mimic and miR-26a-5p inhibitor) was detected by qPCR. The expression level of U6 was used as an internal reference for miR-26a-5p. The data are shown as the mean ± standard deviation. (B) Binding site sequences of miR-26a-5p and PTGS2 3 ‘UTR. (C) Luciferase activity of WT or Mut PTGS2 after co-transfection of miR-26a-5p mimic and WT or Mut PTGS2 dual-fluorescent vector into SH-SY5Y cells. (D) The effects of miR-26a-5p mimic and mir-26a-5p inhibitor on the expression of PTGS in AD model cells (Aβ25–35-treated SH-SY5Y cells) were detected by qPCR. (E) The effects of miR-26a-5p mimic and miR-26a-5p inhibitor on the vitality of AD model cells (Aβ25–35-treated SH-SY5Y cells) measured using the CCK-8 assay. (F) The effects of cotransfection (pCDH-PTGS2 and miR-26a-5p mimic) on the vitality of AD model cells (Aβ25–35-treated SH-SY5Y cells) measured using the CCK-8 assay. (G,H) The effects of cotransfection (pCDH-PTGS2 and miR-26a-5p mimic) on the proliferation of AD model cells (Aβ25–35-treated SH-SY5Y cells) measured using the soft agar assay. Scales: 10 × 40. The data are shown as the mean ± standard deviation. The horizontal line indicates the comparison between groups at both ends, and the non-horizontal line indicates the comparison with the control group. AD, Alzheimer’s disease. ***p < 0.001; **p < 0.01; *p < 0.01.